Natural Killer Cell

The FDA granted orphan drug designation to oNKord, an investigational natural killer cell-based therapy, for the treatment of multiple myeloma, according to the agent’s manufacturer.

NantKwest and ImmunityBio have partnered on a phase 2 trial to examine the efficacy and safety of a chemoimmunotherapy regimen for treatment of metastatic or locally advanced pancreatic cancer.

NantKwest and ImmunityBio have partnered on a phase 2 trial to examine the efficacy and safety of a chemoimmunotherapy regimen for treatment of metastatic or locally advanced pancreatic cancer.

The FDA cleared an investigational new drug application for CYNK-001 for the treatment of adults with COVID-19 infection, according to the agent’s manufacturer.

The FDA cleared an investigational new drug application for KP1237, a CD38-targeting antibody-recruiting molecule, in combination with autologous natural killer cells for the treatment of patients with multiple myeloma who previously underwent hematopoietic stem cell transplantation.

Natural killer cells transduced with chimeric antigen receptors induced high response rates among patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and chronic lymphocytic leukemia, according to results of a phase 1/phase 2 study published in The New England Journal of Medicine.

The FDA cleared an investigational new drug application for CYNK-001, a natural killer cell therapy, for the treatment of glioblastoma multiforme.

Cytovia Therapeutics announced research partnerships with both The New York Stem Cell Foundation Research Institute and University of California, San Francisco, for the development of induced pluripotent stem cell-derived chimeric antigen receptor-natural killer cell therapies for cancer.

ORLANDO — Two major impediments to widespread adoption of chimeric antigen receptor T-cell therapies are their cost and antigen loss that makes them less effective over time. An allogeneic approach that combines CARs and natural killer cells into one therapy may be the solution, according to preclinical research presented at ASH Annual Meeting and Exposition.

NATIONAL HARBOR, Md. — Allogeneic activated natural killer cell therapy resulted in some antitumor activity with no serious side effects in patients with metastatic Merkel cell carcinoma, according to the results of a phase 2 study presented at the SITC Annual Meeting.